A detailed history of Livelsberger Financial Advisory transactions in Biogen Inc. stock. As of the latest transaction made, Livelsberger Financial Advisory holds 100 shares of BIIB stock, worth $15,871. This represents 0.41% of its overall portfolio holdings.

Number of Shares
100
Holding current value
$15,871
% of portfolio
0.41%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$189.07 - $236.8 $18,907 - $23,680
100 New
100 $19.4 Million
Q4 2023

Mar 22, 2024

BUY
$222.59 - $267.94 $22,259 - $26,794
100 New
100 $25.9 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.9B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Livelsberger Financial Advisory Portfolio

Follow Livelsberger Financial Advisory and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Livelsberger Financial Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Livelsberger Financial Advisory with notifications on news.